Showing results (21-30 of 206) with videos related to
Sort By:
Pageof 21
Current Treatment Options in Oncology|October 28, 2018
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic LeukemiaAnthony M Hunter, Ling Zhang, Eric PadronClinical Advances in Hematology & Oncology : H&O|June 14, 2014
The clinical management of chronic myelomonocytic leukemiaEric Padron, Rami Komrokji, Alan F ListBest Practice & Research. Clinical Haematology|April 1, 2019
TP53 and therapy-related myeloid neoplasmsJae Chung, David A Sallman, Eric PadronBest Practice & Research. Clinical Haematology|December 6, 2021
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDSLuis E Aguirre, Rami Komrokji, Eric PadronCurrent Treatment Options in Oncology|October 4, 2011
The 5q- syndrome: biology and treatmentEric Padron, Rami Komrokji, Alan F ListBlood|October 7, 2016
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemiaMarkus Ball, Alan F List, Eric PadronCancer Biology & Medicine|November 4, 2016
Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromesJoseph A Clara, David A Sallman, Eric PadronCancer Control : Journal of the Moffitt Cancer Center|October 9, 2012
Advances in the management of myelofibrosisRami S Komrokji, Srdan Verstovsek, Eric Padron, et al.Clinical Lymphoma, Myeloma & Leukemia|December 3, 2013
Prognostic factors and risk models in myelodysplastic syndromesRami S Komrokji, Eric Padron, Jeffrey E Lancet, et al.JCO Clinical Cancer Informatics|April 18, 2019
Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor HeterogeneityMeghan C Ferrall-Fairbanks, Markus Ball, Eric Padron, et al.Pageof 21